News

STAT4d
Amgen loses $400 million antitrust battle to Regeneron
Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
Yahoo Finance21d
Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call
Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor ...
Morningstar29d
Regeneron Announces Investor Conference Presentations
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Fintel on MSN6d
Citigroup Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...
Regeneron wins over $400M jury award as Amgen found liable in antitrust case
Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...